Upper Egypt Local Development Program Selects Esri Software for Data-Driven Governance
2.9.2021 16:42:00 EEST | Business Wire | Press release
When the United Nations adopted the Sustainable Development Goals (SDGs) as a global call to action to achieve a more sustainable future for all by 2030, many countries committed to the cause. Egypt, which launched its strategy in 2016, met the obstacle of geographic disparities due to the need for development in the upper region of the nation. To address this challenge, the Egyptian Ministry of Local Development and the World Bank launched the Upper Egypt Local Development Program (UELDP) a year later.
One vital step toward improving development in Upper Egypt—and part of UELDP—includes establishing a GIS infrastructure in the region. To achieve this, UELDP chose location intelligence world leader Esri to provide the region's new GIS unit with all the required hardware, software, data, and applications necessary for managing complex geospatial data.
"This is a strategically important project, which will play a vital role in driving sustainable, impactful urban planning and development to support communities in Upper Egypt," said Dr. Mohamed Misbah, director for the Middle East and Africa region at Khatib & Alami (K&A), an Esri Platinum partner.
The project will leverage a unified geodatabase and a map viewer to explore geostatistical information and generate reports, graphics, and thematic maps. It will also employ mobile applications for data collection that allow government staff to access data from the field. These services, in addition to operational dashboards, will provide a holistic view for policy makers.
Laying the foundation for asset management systems at the governorate (jurisdictional) level, Esri’s ArcGIS software helps integrate them with databases in relevant ministries and central government agencies. This enables these organizations to comprehensively display vast amounts of statistical and spatial information to support long-term planning and execution in line with UELDP's vision and future goals.
Further strengthening the governorates' capacities, GIS will enable local development data to be georeferenced to support decision-making. The implementation of this system was awarded to Esri partners ProSyLab and K&A.
"ProSyLab, as an Esri partner, adds to its achievements [by] participating in this national project," said Mahmoud Moursi, ProSyLab chairman. "The project aims to help the public sector, represented by the UELDP, in establishing a GIS infrastructure, which promotes the concept of data sharing, facilitating the decision-making process, and building capacity."
UELDP aims to localize sustainable development, create new job opportunities, improve the economy, and strengthen government capacity for quality infrastructure and service delivery in select governorates in Upper Egypt. It was piloted in the Qena and Sohag Governorates to address existing development gaps and has met with success, leading to national policy reforms, and even inspiring a scaled-up version of the program for Egypt's 2019 Decent Life initiative.
To learn more about how UELDP is using technology to enhance public services, visit ueldp.gov.eg.
About K&A
Khatib & Alami (K&A) is an international multidisciplinary consultancy composed of architects, engineers, planners, technologists and other project specialists. With 6,000 people in more than 30 locations, K&A has vast experience working at the forefront of fast changing urban environments, with a deep understanding of delivering complex major projects within agreed time frames and budgets.
Since launching its Geospatial Systems Integration division in 1988, K&A has become one of the leaders in its field, with a 200-strong team of GIS experts. K&A helps government and private sector clients make sense of the vast quantities of information and data available to them, providing insight, enabling better decision-making, creating efficiencies, and improving customer experiences. As an Esri Platinum partner, K&A continuously provides innovative smart solutions that address business challenges and exceed customers' expectations. For more information visit www.khatibalami.com.
About ProSyLab
ProSyLab is an information and communications technology company started in 1994. Since then, ProSyLab solutions have supported various customers in both the private and public sectors across Egypt as well as the Middle East.
ProSyLab (PSL) has a unique spirit and expertise which converts challenges into new success stories. With a portfolio of five companies in different market segments, ProSyLab has been supporting private sector and governmental enterprises across Egypt as well as the Middle East. PSL's innovative ideas and solutions are not merely our philosophy, but also our everyday reality. We remain dedicated to leading the world into a more prosperous and progressive future: by enhancing the world to become more diverse, more tolerant, and more just.
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com.
Copyright © 2021 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005507/en/
Contact information
Jo Ann Pruchniewski
Public Relations, Esri
Mobile: 301-693-2643
Email: jpruchniewski@esri.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
